Erika Hamilton Selected Research

Erika Hamilton Research Topics

Disease

40	Neoplasms (Cancer) 01/2024 - 09/2011
39	Breast Neoplasms (Breast Cancer) 01/2024 - 01/2011
7	Brain Neoplasms (Brain Tumor) 01/2021 - 01/2011
5	Disease Progression 01/2024 - 01/2018
5	Ovarian Neoplasms (Ovarian Cancer) 01/2024 - 10/2019
5	Triple Negative Breast Neoplasms 12/2022 - 01/2014
3	Thrombocytopenia (Thrombopenia) 01/2022 - 01/2018
3	Fatigue 01/2022 - 01/2018
3	Vomiting 01/2022 - 01/2018
3	Diarrhea 01/2021 - 01/2018
2	Uterine Cervical Neoplasms (Cancer of the Cervix) 05/2023 - 10/2017
2	Uterine Neoplasms (Uterine Cancer) 05/2023 - 01/2019
2	Ovarian Epithelial Carcinoma 01/2023 - 01/2020
2	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2023 - 01/2022
2	Pneumonia (Pneumonitis) 01/2023 - 01/2022
2	Neoplasm Metastasis (Metastasis) 09/2022 - 01/2014
2	Circulating Neoplastic Cells 01/2022 - 12/2018
2	Nausea 01/2020 - 01/2018
1	Biliary Tract Neoplasms (Biliary Tract Cancer) 09/2023
1	Arthralgia (Joint Pain) 07/2023
1	Hot Flashes 07/2023
1	Carcinogenesis 06/2023
1	Hematologic Neoplasms (Hematological Malignancy) 05/2023
1	Endometrial Neoplasms (Endometrial Cancer) 01/2023
1	Asthenia 01/2023
1	Dehydration (Water Stress) 01/2022
1	Anemia 01/2022

Drug/Important Bio-Agent (IBA)

12	Hormones (Hormone)IBA 06/2023 - 04/2016
10	Trastuzumab (Herceptin)FDA Link 09/2023 - 02/2012
9	human ERBB2 proteinIBA 05/2023 - 01/2018
9	Biomarkers (Surrogate Marker)IBA 01/2023 - 09/2011
7	Immunoconjugates (Immunoconjugate)IBA 01/2024 - 10/2019
7	Estrogen ReceptorsIBA 07/2023 - 10/2011
6	Ado-Trastuzumab EmtansineIBA 01/2024 - 01/2018
6	tucatinibIBA 09/2023 - 01/2018
5	niraparibIBA 01/2024 - 01/2022
5	ErbB Receptors (EGF Receptor)IBA 09/2023 - 01/2021
4	trastuzumab deruxtecanIBA 01/2024 - 01/2022
4	Fulvestrant (Faslodex)FDA Link 07/2023 - 01/2020
4	Monoclonal AntibodiesIBA 01/2023 - 02/2012
4	PlatinumIBA 01/2023 - 01/2019
4	abemaciclibIBA 08/2022 - 12/2020
4	Capecitabine (Xeloda)FDA Link 01/2021 - 01/2018
3	AntibodiesIBA 01/2024 - 06/2012
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2024 - 01/2022
3	LigandsIBA 06/2023 - 12/2018
3	sacituzumab govitecanIBA 05/2023 - 01/2022
3	Paclitaxel (Taxol)FDA LinkGeneric 01/2023 - 01/2022
3	taxaneIBA 01/2023 - 01/2018
3	Tamoxifen FDA LinkGeneric 08/2022 - 10/2013
3	Bevacizumab (Avastin)FDA Link 01/2022 - 12/2013
3	pertuzumabIBA 01/2020 - 01/2018
3	Tyrosine Kinase InhibitorsIBA 01/2018 - 02/2012
2	Proteins (Proteins, Gene)FDA Link 01/2023 - 06/2012
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 10/2022 - 10/2021
2	palbociclibIBA 01/2022 - 04/2016
2	Circulating Tumor DNAIBA 01/2022 - 12/2018
2	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 12/2013
2	AZD9496IBA 01/2022 - 12/2018
2	AlpelisibIBA 01/2021 - 01/2020
2	Cyclin-Dependent Kinase 4IBA 01/2021 - 01/2020
2	atezolizumabIBA 01/2019 - 01/2019
2	B7-H1 AntigenIBA 01/2019 - 01/2019
2	130-nm albumin-bound paclitaxelIBA 01/2019 - 12/2013
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 04/2016 - 01/2011
2	VaccinesIBA 06/2012 - 02/2012
2	Tyrosine (L-Tyrosine)FDA Link 06/2012 - 09/2011
1	DHES0815AIBA 01/2024
1	TabletsIBA 01/2024
1	margetuximabIBA 11/2023
1	snake venom protein C activatorIBA 07/2023
1	Estrogens (Estrogen)FDA Link 07/2023
1	Cytotoxins (Cytolysins)IBA 05/2023
1	mirvetuximab soravtansineIBA 05/2023
1	AntigensIBA 05/2023
1	tisotumab vedotinIBA 05/2023
1	Progesterone Receptors (Progesterone Receptor)IBA 01/2023
1	zanidatamabIBA 12/2022
1	Surface Antigens (Surface Antigen)IBA 12/2022
1	CalciumIBA 12/2022
1	Glycoproteins (Glycoprotein)IBA 12/2022
1	FCN-437cIBA 10/2022
1	rucaparibIBA 01/2022
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022
1	RAD140IBA 01/2022
1	Programmed Cell Death 1 ReceptorIBA 01/2022
1	dostarlimabIBA 01/2022
1	Androgen Receptors (Androgen Receptor)IBA 01/2022
1	BilirubinIBA 01/2022
1	ribociclibIBA 01/2021
1	NVP-BKM120IBA 01/2021
1	AntidiarrhealsIBA 01/2021

Therapy/Procedure

32	Therapeutics 01/2024 - 09/2011
9	Drug Therapy (Chemotherapy) 07/2023 - 12/2013
2	Aftercare (After-Treatment) 01/2022 - 01/2018
1	Immunotherapy 05/2023
1	Traction 05/2023
1	Precision Medicine 01/2022
1	Adjuvant Chemotherapy 01/2022
1	Drug Tapering 01/2021